← Back to Home

argenx to acquire UNP for up to $1.15 billion, expanding from antibodies into macrocyclic peptide drugs

With a $550 million upfront payment to acquire its existing partner, argenx will bring macrocyclic peptide discovery capabilities into its immunology strategy. Oral and long-acting drugs are the goal, but the announcement has not disclosed specific drug candidates or results from human studies.

By SURL BioNews

Whether new drugs for immune diseases can be taken orally or deliver longer-lasting effects with each dose depends on the design of the drug molecules themselves. argenx, known for its antibody engineering expertise, is expanding its research and development toolkit to explore these possibilities: on November 9, the company announced that it would acquire Unnatural Products (UNP), which specializes in macrocyclic peptides, in a transaction with a potential total value of up to approximately $1.15 billion.

Under the agreement, argenx will pay $550 million upfront from existing cash, with up to an additional $595 million payable upon achievement of specified development and regulatory milestones. The maximum transaction value therefore does not represent an acquisition payment due immediately. Both companies’ boards have approved the transaction, which is expected to close before year-end, subject to customary closing conditions.

The acquisition builds on more than two years of collaboration and investment between the companies. argenx already held a minority equity stake in UNP and will now acquire the remaining shares. DLA Piper, a legal adviser involved in the transaction, also confirmed that the arrangement will combine UNP’s macrocyclic peptide expertise with argenx’s antibody engineering and immune disease development capabilities.

Macrocyclic peptides are peptide molecules with a ring-shaped structure, offering an alternative to antibodies in drug design. argenx hopes to use them to explore new disease biology and develop oral or long-acting drugs for severe immune-mediated diseases. However, having a platform for discovering these molecules does not mean that the resulting drugs can be absorbed orally or sustain their effects long enough in humans; these properties still require validation for each drug.

After closing, UNP’s existing team and management will remain in Santa Cruz, California, in the United States, and the site will become argenx’s peptide discovery hub. UNP will continue to lead drug discovery under a strategic framework agreed upon by both companies, while argenx will provide clinical development and commercialization capabilities to support the subsequent work from molecular design to bringing drugs to market.

The announcement currently does not list specific drug candidates, disease targets or human trial data covered by the acquisition, nor does it disclose the detailed terms of the individual milestones. The transaction establishes the direction of argenx’s expansion of its research and development capabilities; whether the convenience of oral treatment or long-acting dosing becomes an option available to patients will still depend on absorption, efficacy and safety data from the drugs developed subsequently.

References

  1. argenx